These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 19058218)
1. How different are luminal A and basal breast cancers? Bertucci F; Finetti P; Cervera N; Charafe-Jauffret E; Buttarelli M; Jacquemier J; Chaffanet M; Maraninchi D; Viens P; Birnbaum D Int J Cancer; 2009 Mar; 124(6):1338-48. PubMed ID: 19058218 [TBL] [Abstract][Full Text] [Related]
2. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877 [TBL] [Abstract][Full Text] [Related]
3. Integrated profiling of basal and luminal breast cancers. Adélaïde J; Finetti P; Bekhouche I; Repellini L; Geneix J; Sircoulomb F; Charafe-Jauffret E; Cervera N; Desplans J; Parzy D; Schoenmakers E; Viens P; Jacquemier J; Birnbaum D; Bertucci F; Chaffanet M Cancer Res; 2007 Dec; 67(24):11565-75. PubMed ID: 18089785 [TBL] [Abstract][Full Text] [Related]
4. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype. Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807 [TBL] [Abstract][Full Text] [Related]
5. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Finetti P; Cervera N; Charafe-Jauffret E; Chabannon C; Charpin C; Chaffanet M; Jacquemier J; Viens P; Birnbaum D; Bertucci F Cancer Res; 2008 Feb; 68(3):767-76. PubMed ID: 18245477 [TBL] [Abstract][Full Text] [Related]
6. Semaphorin-plexin signalling genes associated with human breast tumourigenesis. Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246 [TBL] [Abstract][Full Text] [Related]
7. ESPL1 is a candidate oncogene of luminal B breast cancers. Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634 [TBL] [Abstract][Full Text] [Related]
8. An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. Melchor L; Benítez J Carcinogenesis; 2008 Aug; 29(8):1475-82. PubMed ID: 18596026 [TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt? Loi S Eur J Cancer; 2008 Dec; 44(18):2813-8. PubMed ID: 18990560 [TBL] [Abstract][Full Text] [Related]
10. A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543 [TBL] [Abstract][Full Text] [Related]
11. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Bergamaschi A; Kim YH; Wang P; Sørlie T; Hernandez-Boussard T; Lonning PE; Tibshirani R; Børresen-Dale AL; Pollack JR Genes Chromosomes Cancer; 2006 Nov; 45(11):1033-40. PubMed ID: 16897746 [TBL] [Abstract][Full Text] [Related]
12. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. Han W; Jung EM; Cho J; Lee JW; Hwang KT; Yang SJ; Kang JJ; Bae JY; Jeon YK; Park IA; Nicolau M; Jeffrey SS; Noh DY Genes Chromosomes Cancer; 2008 Jun; 47(6):490-9. PubMed ID: 18314908 [TBL] [Abstract][Full Text] [Related]
14. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. Helms MW; Packeisen J; August C; Schittek B; Boecker W; Brandt BH; Buerger H J Pathol; 2005 Jul; 206(3):366-76. PubMed ID: 15892165 [TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Bertucci F; Finetti P; Cervera N; Charafe-Jauffret E; Mamessier E; Adélaïde J; Debono S; Houvenaeghel G; Maraninchi D; Viens P; Charpin C; Jacquemier J; Birnbaum D Cancer Res; 2006 May; 66(9):4636-44. PubMed ID: 16651414 [TBL] [Abstract][Full Text] [Related]
16. Evidence for a transcriptional signature of breast cancer. Feng Y; Li X; Sun B; Wang Y; Zhang L; Pan X; Chen X; Wang X; Wang J; Hao X Breast Cancer Res Treat; 2010 Jul; 122(1):65-75. PubMed ID: 19728083 [TBL] [Abstract][Full Text] [Related]
17. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis. Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801 [TBL] [Abstract][Full Text] [Related]
18. Identification of molecular apocrine breast tumours by microarray analysis. Farmer P; Bonnefoi H; Becette V; Tubiana-Hulin M; Fumoleau P; Larsimont D; Macgrogan G; Bergh J; Cameron D; Goldstein D; Duss S; Nicoulaz AL; Brisken C; Fiche M; Delorenzi M; Iggo R Oncogene; 2005 Jul; 24(29):4660-71. PubMed ID: 15897907 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive molecular portraits of human breast tumours. Cancer Genome Atlas Network Nature; 2012 Oct; 490(7418):61-70. PubMed ID: 23000897 [TBL] [Abstract][Full Text] [Related]
20. The genomic profile of HER2-amplified breast cancers: the influence of ER status. Marchiò C; Natrajan R; Shiu KK; Lambros MB; Rodriguez-Pinilla SM; Tan DS; Lord CJ; Hungermann D; Fenwick K; Tamber N; Mackay A; Palacios J; Sapino A; Buerger H; Ashworth A; Reis-Filho JS J Pathol; 2008 Dec; 216(4):399-407. PubMed ID: 18810758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]